| 0 (0%) | 09-27 09:27 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 30.24  |
1-year : | 33.83 |
| Resists | First : | 25.89 |
Second : | 28.96 |
| Pivot price | 24.12 |
|||
| Supports | First : | 20.93 |
Second : | 17.41 |
| MAs | MA(5) : | 22.8 |
MA(20) : | 25.1 |
| MA(100) : | 21.32  |
MA(250) : | 24.94 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 8.5 |
D(3) : | 7 |
| RSI | RSI(14): 33.7 |
|||
| 52-week | High : | 35.72 | Low : | 16.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ APLS ] has closed above bottom band by 20.8%. Bollinger Bands are 32.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.4 - 22.54 | 22.54 - 22.67 |
| Low: | 20.63 - 20.78 | 20.78 - 20.92 |
| Close: | 22.12 - 22.36 | 22.36 - 22.59 |
Sat, 27 Sep 2025
What drives APLS stock price - Technical Analysis Insights & Swing Trade Smarter With Data Insights - Early Times
Fri, 26 Sep 2025
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) with Low - GuruFocus
Fri, 26 Sep 2025
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down After Analyst Downgrade - MarketBeat
Fri, 26 Sep 2025
Apellis stock cut to sell at Goldman Sachs (APLS:NASDAQ) - Seeking Alpha
Fri, 26 Sep 2025
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Sell Rating by The Goldman Sachs Group - MarketBeat
Fri, 19 Sep 2025
APLS delays decision on Fairhope Public Library funding - Alabama Political Reporter
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 126 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 13.6 (%) |
| Held by Institutions | 105.7 (%) |
| Shares Short | 20,540 (K) |
| Shares Short P.Month | 22,090 (K) |
| EPS | -1.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.24 |
| Profit Margin | -30.3 % |
| Operating Margin | -18.7 % |
| Return on Assets (ttm) | -13.8 % |
| Return on Equity (ttm) | -108.5 % |
| Qtrly Rev. Growth | -10.7 % |
| Gross Profit (p.s.) | 2.48 |
| Sales Per Share | 5.97 |
| EBITDA (p.s.) | -1.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 4 (M) |
| Levered Free Cash Flow | 106 (M) |
| PE Ratio | -12.23 |
| PEG Ratio | 0 |
| Price to Book value | 18.04 |
| Price to Sales | 3.74 |
| Price to Cash Flow | 629.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|